Navigation Links
Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
Date:6/1/2009

nic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers and multiple myeloma. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Initial Clinical Results for ENMD-2076
2. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
3. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
4. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
5. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
6. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
7. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
8. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
9. EntreMed to Present at The New York Society of Security Analysts Industry Conference
10. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
11. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Mass. , July 2, 2015   ... and European retinal specialists identify less frequent dosing ... edema (DME), due to the burden on both ... anti-vascular endothelial growth factor (VEGF) injections, which are ... Allergan/Molecular Partners, abicipar pegol, which is in development ...
(Date:7/2/2015)... SHENZHEN, China , 2. Juli 2015 /PRNewswire/ ... Hochdurchsatz-Labor für DNA-Screening in Hongkong vom American ... BGI-Einrichtung in Hongkong ist das erste klinische ... ein CAP-Zertifkat erhält und somit ... Ergänzend zu den bestehenden US FDA - ...
(Date:7/2/2015)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... and tissue hypothermic storage and cryopreservation freeze ... chain management app for smart shippers ("BioLife" ... has included BioLife in its annual list of the ... state for 2015. Now in its ...
Breaking Medicine Technology:Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 3
... (MARKET WIRE) -- July 06, ... <a target="_blank" href=,'http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB"%3EDORB'>,http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB">DORB ),("DOR" or ... the European Patent,Office has granted ... with claims related to,oral vaccination ...
... in The Lancet on TMC125, an Investigational ... /PRNewswire/ -- Data from two,ongoing Phase 3 ... adult patients with documented non-nucleoside reverse,transcriptase inhibitor ... undetectable viral load (defined as achieving,confirmed undetectable ...
Cached Medicine Technology:DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 6TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
(Date:7/3/2015)... , ... July 03, 2015 , ... " Selfie on ... which features the latest and coolest technology products available to consumers. Amanda Forstrom, a ... how these selfie sticks are great for documenting memories. , Almost every smartphone has ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce ... sweetFrog store located in the Lone Star State. The premium frozen yogurt chain was listed ... store, which opened June 19 in the Village at Bachman Lake, is located at:, 3701 ...
(Date:7/2/2015)... Lincoln, RI (PRWEB) , ... July 02, 2015 , ... ... keep safety in mind. That’s why Amica Insurance is sharing some tips ... Safety Commission (CPSC), approximately 230 people go to the emergency room daily with fireworks-related ...
(Date:7/2/2015)... PEACHTREE CITY, GA (PRWEB) , ... July 02, ... ... or field sporting the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the ... physicians, fitness experts and athletic trainers. Their significant popularity has inspired four new, ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... Healthcare Delivery Coalition met for the late June Web-based session, the speakers discussed ... reimbursement schemes and managing high-risk patients through coordinated care. , During the session, ...
Breaking Medicine News(10 mins):Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:6 Fireworks Safety Tips from Amica Insurance 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 2Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 4
... 12 /PRNewswire-FirstCall/ - Innolife Pharma, Inc.,(Other OTC:INNP.PK - ... eight,months regarding the formation of a joint venture ... where final written terms have been,submitted on all ... very first,product acquisition. It should be noted that ...
... MED3OOO Group, Inc. (MED3OOO), a,national healthcare management ... owned subsidiary of MED3OOO, for billing, marketing, and,business ... member of the South,Carolina Provider Outreach and Education ... invited select members that represent key groups,from the ...
... million, OWINGS MILLS, Md., May 12 Medifast, Inc.,(NYSE: ... the period,ended March 31, 2008., Financial highlights included:, ... margins increased to 75.8% vs. 74.8%, -- The direct ... increase of 63% year-over-year;, -- Medifast ...
... and the Dreaded Summer Yeast Infection, OAKLAND, Calif., May ... brings health and beauty issues that many women,aren,t prepared for., ... Nature,s Cure for,avoiding some elusive summertime pitfalls., From The ... as to skin! After,just one hour of exposure, hair begins ...
... of Pay-for-Performance Programs , At a time ... that while such programs may succeed in improving ... change the nature of patient consultations and the ... with 41 family physicians and nurses working in ...
... Myanmar Relief Fund,( http://www.MyanmarReliefFund.org ) is a coalition ... know-how to get aid in and directly to ... treating the,injured, and a myriad of supplies are ... a coalition of private American and Myanmar,citizens with ...
Cached Medicine News:Health News:Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture 2Health News:PSA, LLC, a MED3OOO Company, Selected as a Member of the SC Provider Outreach and Education Advisory Group 2Health News:PSA, LLC, a MED3OOO Company, Selected as a Member of the SC Provider Outreach and Education Advisory Group 3Health News:Medifast Announces First Quarter 2008 Financial Results 2Health News:Medifast Announces First Quarter 2008 Financial Results 3Health News:Medifast Announces First Quarter 2008 Financial Results 4Health News:Medifast Announces First Quarter 2008 Financial Results 5Health News:Medifast Announces First Quarter 2008 Financial Results 6Health News:Medifast Announces First Quarter 2008 Financial Results 7Health News:Medifast Announces First Quarter 2008 Financial Results 8Health News:A Woman's Summertime Guide to Healthy Living From Head-to-Toe 2Health News:A Woman's Summertime Guide to Healthy Living From Head-to-Toe 3Health News:May/June 2008 Annals of Family Medicine tip sheet 2Health News:May/June 2008 Annals of Family Medicine tip sheet 3Health News:May/June 2008 Annals of Family Medicine tip sheet 4Health News:May/June 2008 Annals of Family Medicine tip sheet 5Health News:May/June 2008 Annals of Family Medicine tip sheet 6
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Paraffin Block Storage System...
The Tissue Cassette Storage Cabinet is made of strong, laminated fiberboard....
Plastic Block Filing Cabinet is a durable, six-drawer unit that holds up to 1500 slides....
Medicine Products: